NSCLC Clinical Trial
— ALK2016CPHGOfficial title:
CHARACTERISTICS OF ADULT PATIENTS TREATED WITH CRIZOTINIB FOR ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH ALK GENE REARRANGEMENT OR ROS1 GENE REARRANGEMENT IN GENERAL HOSPITALS.
| Verified date | September 2021 |
| Source | Pfizer |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational [Patient Registry] |
Descriptive Observational Study. Characteristics Of ALK-positive and ROS1-positive Adults Patients Non-Small Cell Lung Cancer (NSCLC) Treated With Crizotinib Within General Hospitals
| Status | Completed |
| Enrollment | 71 |
| Est. completion date | July 1, 2020 |
| Est. primary completion date | July 1, 2020 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion criteria - Age = 18 years - Locally advanced or metastatic NSCLC - Patient ALK gene rearrangement or ROS1 gene rearrangement - Patient having initiated in the previous 3 months or patient initiating crizotinib treatment regardless of the line of treatment - Patient followed up by a physician in a hospital pulmonary medicine department - Subject of reproductive age, using an effective method of contraception - Patient informed verbally and in writing on the study and having consented to his/her personal data being collected within the scope of the study. Non-inclusion criteria - Patient included within the scope of an interventional therapeutic trial - Patient not presenting with ALK gene rearrangement or ROS1 gene rearrangement - Patient not available for follow-up throughout the duration of the study - Patient deemed to be incapable of responding to the study questions for linguistic, cognitive or organisational reasons. |
| Country | Name | City | State |
|---|---|---|---|
| France | Centre Hospitalier Intercommunal du Pays d'Aix-Pertuis,Service de Pneumologie | Aix en Provence | |
| France | Clinique de l Europe | Amiens | |
| France | Hopital Robert Ballanger, Service de Pneumologie | Aulnay sous Bois | |
| France | Centre Hospitalier d Avignon | Avignon | |
| France | Centre Hospitalier de Beauvais | Beauvais | |
| France | Centre Hospitalier General Beziers, Service De Pneumologie | Beziers | |
| France | Centre Hospitalier de Cannes | Cannes | |
| France | Centre Hospitalier Chalon sur Saone William Morey | Chalon sur Saone | |
| France | Centre Hospitalier Metropole de Savoie-Site de Chambery | Chambery | |
| France | Hopitaux Civils de Colmar - Hopital Louis Pasteur | Colmar Cedex | |
| France | Centre Hospitalier ALPES LEMAN | Contamine sur Arve | |
| France | Centre Hospitalier Intercommunal Frejus | Frejus | |
| France | CHD Vendee | La Roche Sur Yon | |
| France | Centre Hospitalier Départemental Les Oudairies | La Roche Sur Yon Cedex 9 | |
| France | Le Mans Hospital Center | Le Mans | |
| France | Centre Hospitalier des Deux Vallees - Longjumeau BP 125 | Longjumeau | |
| France | Centre Hospitalier de Macon | Macon cedex | |
| France | Hopital Europeen - Service de Pneumologie | Marseille | |
| France | GHR Mulhouse Sud Alsace | Mulhouse | |
| France | Centre Hospitalier de l'Agglomeration de Nevers | Nevers | |
| France | Centre Hospitalier Regional d Orleans | Orleans | |
| France | Centre Hospitalier Annecy Genevois | Pringy | |
| France | Groupe Hospitalier Sud Reunion | Saint Pierre La Réunion | |
| France | Hopitaux du Leman | Thonon les Bains | |
| France | Centre Hospitalier de Troyes, Service de Pneumologie - Oncologie Thoracique | Troyes | |
| France | Centre Hospitalier de Villefranche sur Saone - BP80436 | Villefranche sur Saone |
| Lead Sponsor | Collaborator |
|---|---|
| Pfizer | French College of General Hospital Pneumologists (CPHG) |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Demographical Characteristics of Participants | Baseline up tp Month 18 | ||
| Secondary | Number of subjects using the diagnostic method used to detect ALK (Anaplastic lymphoma kinase) gene rearrangement | Baseline | ||
| Secondary | Number of Participants With Clinical Response through Month 18 | Month 3, Month 6, Month 9, Month 12, Month 15, Month 18 | ||
| Secondary | Objective Tumor Response | Baseline up to month 18 | ||
| Secondary | Progression-Free Survival (PFS) | Baseline up to Month 18 | ||
| Secondary | Number of participants with a change from baseline in (QLQ-LC 13) Quality of life Questionnaire for Lung Cancer | Baseline through Month 18 | ||
| Secondary | Change from baseline Morisky self-administered questionnaire | Baseline through month 18 | ||
| Secondary | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerabitly] | Time from first dose of study drug though month 18 | ||
| Secondary | Number of subjects using diagnostic method used to detect ROS1 gene rearrangement | Baseline | ||
| Secondary | Overall Survival (OS) | Baseline , Month 12, Month 18 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05821933 -
RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03269162 -
Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection
|
Phase 3 | |
| Recruiting |
NCT05002270 -
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06315686 -
The Dynamic Monitoring of Cerebrospinal Fluid ctDNA
|
Phase 2 | |
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Recruiting |
NCT05466149 -
Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion
|
Phase 2 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT03609918 -
Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing
|
||
| Recruiting |
NCT06043817 -
First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
|
Phase 1/Phase 2 | |
| Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
| Recruiting |
NCT05078931 -
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
|
Phase 2 | |
| Not yet recruiting |
NCT05547737 -
Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
|
||
| Not yet recruiting |
NCT05909137 -
Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
|
||
| Withdrawn |
NCT05959473 -
EGFR_IUO 3.20 Clinical Study Protocol
|
N/A | |
| Not yet recruiting |
NCT05005468 -
A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.
|
Phase 2 | |
| Recruiting |
NCT01690390 -
Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease
|
Phase 2 | |
| Completed |
NCT01852578 -
Cabazitaxel in Relapsed and Metastatic NSCLC
|
Phase 2 | |
| Active, not recruiting |
NCT01460472 -
Immunotherapy With Racotumomab in Advanced Lung Cancer
|
Phase 3 | |
| Completed |
NCT00702975 -
Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy
|
Phase 2 | |
| Completed |
NCT00866970 -
Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia
|
Phase 2 |